As ordered reported by the House Committee on Energy and Commerce on February 12, 2015
H.R. 471 would modify certain administrative procedures followed by the Department of Justice in regulating legitimate uses of controlled substances. In addition, within one year of enactment, the bill would require the Department of Health and Human Services to assess the effect of law enforcement activities on access to medications, examine potential benefits to patients from collaborations between governments and stakeholders, and report to the Congress on these matters.
Based on the cost of similar activities, CBO estimates that implementing the bill would cost less than $500,000 over the 2015-2016 period; any spending would be subject to the availability of appropriated funds. Enacting the legislation would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.
H.R. 471 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act and would impose no costs on state, local, or tribal governments.
